Antiprimod presentation at ASH
Callisto Pharmaceuticals, Inc. KAL (FWB:CA4), announced that its anti-cancer drug candidate Atiprimod has been selected for a second Oral presentation of research data at the annual meeting of American Society of Hematology (ASH).
Callisto's research collaborators at Dana-Farber Cancer Institute will present findings of an animal-based study to investigate the effect of Atiprimod on multiple myeloma tumors, a serious, currently incurable form of blood cancer. The animal study, conducted by researchers at Dana-Farber, observed that Atiprimod produced experimentally significant reduction in tumor levels.
The newly-announced abstract, #249, describes Atiprimod's activity in three mouse models of human multiple myeloma in addition to gene expression profiling data observed on cells exposed to Atiprimod. One of the animal models evaluated the effect of Atiprimod on human multiple myeloma cells in a human bone marrow microenvironment. In this model, mice were implanted with a human fetal bone chip engrafted with multiple myeloma cells and treated i.p. with Atiprimod (40 mg/kg) or vehicle alone (PBS) for two weeks. The researchers observed a 60% reduction in the indicator of anti-tumor activity in mice treated with Atiprimod versus control group. To evaluate effects of Atiprimod on primary patient cells in a human microenvironment, mice were engrafted with patient multiple myeloma cells (IgG gamma) and treated i.p. with Atiprimod (50 mg/kg) or vehicle alone (PBS) for 4 weeks. Treatment with Atiprimod induced a reduction in both human IgG and gamma light chain levels in mouse sera, whereas levels of both proteins continued to rise in mice treated with vehicle alone. The molecular changes in multiple myeloma cells induced by Atiprimod were also evaluated using gene expression profiling of multiple myeloma cells exposed to Atiprimod. Atiprimod induced significant down-regulation of genes involved in growth and cell-cycle control, adhesion, cell-signalling pathways, up-regulation of genes implicated in apoptotic cascades and in negative regulation of signal transduction.
Source: www.callistopharma.com
Callisto's research collaborators at Dana-Farber Cancer Institute will present findings of an animal-based study to investigate the effect of Atiprimod on multiple myeloma tumors, a serious, currently incurable form of blood cancer. The animal study, conducted by researchers at Dana-Farber, observed that Atiprimod produced experimentally significant reduction in tumor levels.
The newly-announced abstract, #249, describes Atiprimod's activity in three mouse models of human multiple myeloma in addition to gene expression profiling data observed on cells exposed to Atiprimod. One of the animal models evaluated the effect of Atiprimod on human multiple myeloma cells in a human bone marrow microenvironment. In this model, mice were implanted with a human fetal bone chip engrafted with multiple myeloma cells and treated i.p. with Atiprimod (40 mg/kg) or vehicle alone (PBS) for two weeks. The researchers observed a 60% reduction in the indicator of anti-tumor activity in mice treated with Atiprimod versus control group. To evaluate effects of Atiprimod on primary patient cells in a human microenvironment, mice were engrafted with patient multiple myeloma cells (IgG gamma) and treated i.p. with Atiprimod (50 mg/kg) or vehicle alone (PBS) for 4 weeks. Treatment with Atiprimod induced a reduction in both human IgG and gamma light chain levels in mouse sera, whereas levels of both proteins continued to rise in mice treated with vehicle alone. The molecular changes in multiple myeloma cells induced by Atiprimod were also evaluated using gene expression profiling of multiple myeloma cells exposed to Atiprimod. Atiprimod induced significant down-regulation of genes involved in growth and cell-cycle control, adhesion, cell-signalling pathways, up-regulation of genes implicated in apoptotic cascades and in negative regulation of signal transduction.
Source: www.callistopharma.com
posted by gwg at 8:31 PM
0 Comments:
Post a Comment
<< Home